Clinical characteristics and antibiotic resistance of Shigella gastroenteritis in Ankara, Turkey between 2003 and 2009, and comparison with previous reports  by Özmert, Elif Nursel et al.
International Journal of Infectious Diseases 15 (2011) e849–e853Clinical characteristics and antibiotic resistance of Shigella gastroenteritis in
Ankara, Turkey between 2003 and 2009, and comparison with previous reports
Elif Nursel O¨zmert a, Osman Tolga I˙nce a,*, Emel O¨ru¨n b, Songu¨l Yalc¸ın a, Kadriye Yurdako¨k a, Deniz Gu¨r c
aDepartment of Pediatrics, Social Pediatrics Unit, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey
bDepartment of Pediatrics, Fatih University Faculty of Medicine, Ankara, Turkey
cClinical Microbiology Laboratory, I˙hsan Dog˘ramacı Children’s Hospital, Hacettepe University, Ankara, Turkey
A R T I C L E I N F O
Article history:
Received 3 February 2011
Received in revised form 26 August 2011
Accepted 31 August 2011
Corresponding Editor: Timothy Barkham,
Tan Tock Seng, Singapore
Keywords:
Children
Shigella gastroenteritis
Antibiotic susceptibility
Clinical characteristics
S U M M A R Y
Objectives: The aim of this study was to deﬁne the epidemiological, clinical, and antibiotic susceptibility
patterns of Shigella gastroenteritis cases occurring during the years 2003–2009 and to compare results
with those of the years 1987–2002.
Methods: A hospital-based study was conducted over a 22-year period. All 238 Shigella strains isolated
between 2003 and 2009 were compared to 618 isolates from the period 1987–1994 and 218 Shigella
strains isolated during 1995–2002 with regard to antimicrobial resistance patterns and patient clinical
characteristics.
Results: The predominant species during all periods was Shigella sonnei, with an increasing
predominance across the periods (64.0%, 71.5%, and 87.8%, respectively; p < 0.001). Neither the
prevalence of bloody diarrhea nor other clinical characteristics changed across the study periods, except
for the prevalence of dehydration, which increased (11.0%, 20.6%, and 28.6%, respectively; p < 0.001).
During the period 2003–2009, 69.9% of Shigella were resistant to trimethoprim/sulfamethoxazole, 35.8%
to ampicillin, and 4.7% to nalidixic acid. No case resistant to ciproﬂoxacin was detected. Multidrug
resistance was also found to be similar in the last two periods (24.0% vs. 28.1%, respectively).
Conclusions: There was both a microbiological and a clinical change in childhood Shigella gastroenteritis
cases over the 22 years. The antibiotic resistance pattern appears to have remained stable over the last
two periods. There is a need to re-examine the criteria and clinical management guidelines for suspected
shigellosis cases.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Bloody diarrhea in young children is usually a sign of an
invasive enteric infection that carries a substantial risk of serious
morbidity and death.1,2 Shigella is the most frequently isolated
pathogen from the stools of young children with bloody diarrhea in
developing countries.3 Bloody diarrhea is treated empirically as
shigellosis unless proven otherwise, and it is one of the limited
indications for antibiotic treatment as recommended by the
Diarrheal Diseases Control Program of the World Health Organi-
zation (WHO).4 Appropriate antimicrobial treatment for shigellosis
will reduce the duration and severity of dysentery and may also
prevent lethal complications.5
Four species of Shigella are pathogenic in humans. Shigella sonnei
and Shigella boydii usually cause a relatively mild illness in which
diarrhea may be watery or bloody.6 Shigella ﬂexneri is the chief cause* Corresponding author. Tel.: +90 312 3051133; fax: +90 312 3243284.
E-mail address: oti1974@yahoo.com (O.T. I˙nce).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.08.008of endemic shigellosis in developing countries. Although Shigella
dysenteriae type 1 is associated with the highest case fatality rates,
the majority of deaths from shigellosis worldwide result from
endemic disease, especially that caused by S. ﬂexneri.7
Changes in Shigella epidemiology may change the clinical
presentation as well as the antibiotic resistance patterns.
Recognition of these changes is necessary for appropriate clinical
management.
Resistance to ampicillin and trimethoprim/sulfamethoxazole
(TMP–SMX), formerly the drugs of choice, is now widespread.8–11
Reporting changes in resistance patterns helps maintain effective
empirical antibiotic choices. In this study we report changes in
clinical characteristics and antibiotic resistance patterns of
Shigella cases over time.
2. Materials and methods
This study was conducted among the culture-proven Shigella
cases admitted to Hacettepe University Ihsan Dog˘ramacı Chil-
dren’s Hospital Diarrheal Diseases Training and Treatment Unit,ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Comparison of the clinical characteristics of Shigella gastroenteritis cases across the
three study periods
Clinical characteristic 1987–1994
(n = 618)
1995–2002
(n = 218)
2003–2009
(n = 161)
p-Value
Age group
<1 year 11.0 5.6 2.1
1–5 years 59.0 48.6 29.4
>5 years 30.0 45.8 68.5 <0.001
Bloody diarrhea 37.0 35.8 31.1 0.38
Fever 80.0 83.5 74.5 0.09
Vomiting 53.0 54.6 52.2 0.88
Convulsions 3.0 0.9 3.7 0.16
Dehydration 11.0 20.6 28.6 <0.001
Hospitalization 1.0 2.3 3.1 0.10
Death 0 0 0
Values are % of isolates.
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cultures were obtained from all cases and inoculated in selenite F
broth, Salmonella–Shigella (SS) agar, and eosin–methylene blue
(EMB) agar, and were incubated overnight at 35–37 8C in ambient
air. The following day, subcultures were taken from selenite F
broth and inoculated on SS agar and EMB agar. Lactose-negative
colonies suggesting Shigella species were further tested by routine
biochemical tests and conﬁrmed by slide agglutination tests with
Shigella antisera (Denka, Seiken Co. Ltd, Tokyo, Japan) and BBL
Crystal E/NF identiﬁcation panel (Becton Dickinson, Sparks, MD,
USA).13
In vitro susceptibility to TMP–SMX, ampicillin, nalidixic acid,
and ciproﬂoxacin was determined by the Kirby–Bauer disk
diffusion method following the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines.14 Multidrug resistance was
deﬁned as strains resistant to two or more different classes of
antibiotics.
Patient clinical characteristics were obtained from hospital
ﬁles. Bloody diarrhea was deﬁned as any diarrheal episode in
which the loose or watery stools contain visible red blood observed
macroscopically by the clinicians and/or related by the parents.
Dehydration was evaluated and treated according to WHO
guidelines.12 In this study, 238 Shigella strains isolated between
2003 and 2009 were compared to those isolated and reported
during two previous periods (618 Shigella isolates from the period
1987–199415 and 218 Shigella isolates from the period 1995–
200216) for antimicrobial resistance patterns, clinical character-
istics, and physician antibiotic prescription patterns.
Statistical calculations were performed with SPSS statistical
software v. 11.5 (SPSS, Chicago, IL, USA). The Chi-square test,
Mann–Whitney U-test, and Student t-test were used for statistical
comparisons, as appropriate.
3. Results
Between the years 2003 and 2009, 238 Shigella cases were
identiﬁed (136 male, 102 female). The overall isolation rate of
Shigella sp was 1.6% (238/14 803) during this period. Among the
isolates, 209 (87.8%) were S. sonnei, 25 (10.5%) were S. ﬂexneri, and
four (1.7%) were S. boydii. The comparative distributions of Shigella
sp within the three periods are shown in Figure 1. During the study
period, as in the previous periods, most of the Shigella cases (65.9%;Figure 1. Shigella species during the dip < 0.001) were identiﬁed in the dry and hot season (between July
and October).
The clinical characteristics of the cases and comparison with the
previous periods are shown in Table 1. In our study the mean age of
the cases was 93  48 months (range 5–202 months). S. ﬂexneri was
isolated from younger patients compared with S. sonnei (72.4  68.5
months, 96.9  44.8 months, respectively; p < 0.05), but during the
previous period S. sonnei was isolated from younger patients
compared with S. ﬂexneri (52.8  39.8 months, 70.2  46.6 months,
respectively; p < 0.001). Except for convulsions (p = 0.04), none of the
clinical characteristics differed signiﬁcantly among the different
species during the study period (Table 2).
When the cases were analyzed according to blood in stool, it
was found that, although not statistically signiﬁcant, the Shigella
cases who were admitted with bloody diarrhea were older
(92.6  43.2 months vs. 90.9  46.6 months; p = 0.85), had a higher
daily stool output frequency (8.2  5.5/day vs. 6.9  5.1/day;
p = 0.17), and were hospitalized more frequently (6.0% and 1.8%;
p = 0.15) than the cases without bloody stool.
Approximately 38.5% (62/161) of the cases received antibiotics
on the basis of a clinical suspicion of shigellosis; 40.0% received
antibiotics during 1995–2002 and 43.0% received antibiotics
during 1987–1994. During the study period, 52% (26/50) of the
patients with bloody diarrhea and 32.4% (36/111) of cases withfferent study periods (*p < 0.001).
Table 2
Comparison of clinical characteristics according to Shigella species, 2003–2009
Clinical characteristic Shigella sonnei
(n = 144)
Shigella ﬂexneri
(n = 15)
p-Value
Age group
<1 year 1.0 12.0
1–5 years 26.3 56.0
>5 years 72.7 32.0 <0.001
Bloody diarrhea 31.3 33.3 0.87
Fever 75.7 60.0 0.18
Vomiting 54.2 40.0 0.44
Abdominal pain 46.5 26.7 0.23
Convulsions 2.8 13.3 0.04
Dehydration 27.1 46.7 0.11
Hospitalization 2.8 6.7 0.41
Death 0 0
Values are % of isolates.
Table 3
Antibiotic resistance pattern between the years 2003 and 2009 according to the
Shigella species
Antibiotic Shigella sonnei,
n (%)
Shigella ﬂexneri,
n (%)
Total, n (%)
TMP–SMX 116/162 (71.6) 14/24 (58.3) 130/186 (69.9)
Nalidixic acid 6/173 (3.5) 3/19 (15.8)a 9/192 (4.7)
Ampicillin 65/207 (31.4) 18/25 (72)b 83/232 (35.8)
Ciproﬂoxacin 0/208 (0) 0/25 (0) 0/233 (0)
MDR 56/209 (26.8) 11/25 (44) 67/234 (28.6)
TMP–SMX, trimethoprim/sulfamethoxazole; MDR, multidrug resistance.
a p < 0.05.
b p < 0.001.
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The most frequently prescribed antibiotic was ceﬁxime (46/62),
and there was a sharp increase in the prescription rate of ceﬁxime
(16.3% to 74.2%). As in the previous period, ciproﬂoxacin (6/62) was
the second most commonly prescribed antibiotic during the study
period; the third was ceftriaxone (3/62). TMP–SMX, the most
frequently used antibiotic of the previous periods, was not
prescribed for any patient during the years 2003–2009. Only four
patients’ initial antibiotic therapies (6.6%) were changed to another
antibiotic (all were ciproﬂoxacin) after the results of stool cultures.
Antibiotic therapy was initiated in 21 cases after obtaining the
results of stool cultures, and among these the most frequently
prescribed antibiotic was ciproﬂoxacin (14/21).
The antibiotic resistance patterns as well as multidrug
resistance rates of each Shigella species during the study period
are displayed in Table 3. The most common multidrug resistance
pattern was to TMP–SMX and ampicillin (58 cases), followed by
TMP–SMX and nalidixic acid (6 cases), TMP–SMX, ampicillin, and
nalidixic acid (2 cases), and ampicillin and nalidixic acid (1 case).
Among the multi-resistant species, 66 (98.5%) were resistant to
TMP–SMX, similar to the 1995–2002 period. Comparison of the
antibiotic resistance patterns between the three periods is shown
in Figure 2. Multidrug resistance increased for S. sonnei (6.3% to
26.8%; p < 0.001) and decreased for S. ﬂexneri (71.1% to 44.0%;
p = 0.03) from 1995–2002 to 2003–2009.Figure 2. Antibiotic resistance patterns during the differ4. Discussion
Between the years 1987 and 1994 the Shigella isolation rate at
our center was 3.1%. The isolation rate decreased to 1.6% in the
1995–2002 period and had not changed during the study period
(2003–2009). Our isolation rate is lower than others reported in
our region; for example in Tehran, Iran between the years 2001 and
2006, the Shigella isolation rate was found to be 4.5%.17
Before 1987, S. ﬂexneri was the most common Shigella species
isolated in Turkey.18,19 A similar signiﬁcant species shift has also
been reported in Vietnam and Iran.10,17 However, there are some
countries from our region still reporting S. ﬂexneri as the
predominant species.20,21
Most endemic shigellosis occurs in children aged between 6
months and 3 years.3 At our center, while the number of patients
under 1 year of age has decreased over the years, the number of
patients over 5 years of age has increased. The low isolation rate of
Shigella in those under 1 year of age and the shift of cases to older
age groups may be due to the protective effect of breastfeeding.
Breastfeeding reduces the severity of Shigella infections and shifts
the spectrum of Shigella infections from severe to non-severe
illness.22,23 According to the Turkey Demographic and Health
Survey, 2008, 69% of infants are exclusively breastfed in the ﬁrst 2
months of life. The median duration of breastfeeding for all
children is 16 months.24 However the trends in increased age of
cases cannot be explained solely by prolonged breastfeeding. This
change could be related to changes in referral to our hospital or to
improved hygiene and/or socioeconomic status decreasing the
intensity of enteric pathogen transmission in Ankara, Turkey.ent study periods(*p < 0.001; N/A: not applicable).
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may explain the mild clinical course, low hospitalization rate, and
absence of death among our cases. On the other hand, S. ﬂexneri cases
were found to be younger and more often had bloody diarrhea,
which may be the reason for more frequent antibiotic use and
hospitalization. Dehydration seems to be the most important
emerging complication in our patients, but oral rehydration therapy
appears to be adequate for these cases. However among 238 cases,
only 161 ﬁles were available for the determination of clinical
characteristics. We believe that this may be a drawback of our study
in terms of evaluating the clinical characteristics of our patients.
The ﬁrst choice of antibiotic at our center has changed from
TMP–SMX to ceﬁxime. This may be mostly related to the high
resistance rate to TMP–SMX. High TMP–SMX resistance rates of
between 47.4% and 96.5% are being reported from other
regions.10,11,17,20,25,26 Ampicillin, the second most commonly used
antibiotic during the 1987–1994 period, was not prescribed for any
patient during the years 1995–2002 and was prescribed for only
one patient during the years 2003–2009. The resistance rate to
ampicillin has generally increased since the 1995–2002 period at
our center.16 However another recent article from Turkey18
reported that most strains of Shigella were susceptible to
ampicillin (86.4%). Vinh et al.10 reported a sequential decrease
in resistance to ampicillin, which is now rarely used in Vietnam to
treat gastrointestinal infections. Other reports from our region and
all over the world also indicate high resistance rates (58.4% to 86%)
to ampicillin.17,19,25–27 On the other hand, resistance rates for
ampicillin differ signiﬁcantly among Shigella species. S. ﬂexneri
was found to be highly resistant during all periods (69.0%, 72.9%,
and 72.0%), but the resistance rate of S. sonnei decreased to 5.7% in
the 1995–2002 period and after that increased to 31.4% in the
2003–2009 period. Interestingly Karacan et al.18 reported that
although they found an overall high ampicillin susceptibility rate,
S. ﬂexneri was highly resistant to ampicillin (60.0%). Studies from
Pakistan26 and Vietnam10 have also reported high species-speciﬁc
(S. ﬂexneri) resistance rates to ampicillin, which is also the case in
our country. On the other hand results from the USA28 have shown
similar high resistance rates for both S. sonnei and S. ﬂexneri.
In the 1990s, quinolones emerged as the preferred agents for
the treatment of Shigella. Most authorities recommend an oral
quinolone for proven or suspected shigellosis. Nalidixic acid and
ciproﬂoxacin are highly effective treatment alternatives, despite
reservations about their use in children. However Shigella
resistance to ciproﬂoxacin is increasingly common in India and
in travelers returning from India.29 A recent report from Bangalore,
India, described an increase of resistance to ciproﬂoxacin from 0 to
48% over a 5-year period between 2002 and 2007.30 On the other
hand in both periods of our study there was no Shigella species
resistant to ciproﬂoxacin. Nalidixic acid resistance at our center
was found to be only 4.7%, however nalidixic acid is not available in
Turkey, so is not prescribed.
Multidrug resistance increased slightly at our center between the
last two periods. Multidrug resistance was more common among S.
ﬂexneri cases. This is also in accordance with other reports.21,28
In conclusion, there was a change in the clinical characteristics
of childhood Shigella gastroenteritis at our center over the 22
years, mostly related to the species shift. The antibiotic resistance
pattern appears to have remained stable over the last two periods.
Clinical management guidelines covering the increasing cases of
non-dysenteric shigellosis on admission may be helpful in
decreasing the transmission of this disease in society.
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